MISSION
STATEMENT
Oncology Business Review (OBR) is dedicated exclusively to the business of oncology. OBR provides instantaneous oncology news, provocative journalism, topical discussion, and a place to track performance of oncology products, companies, and people.
ONCOLOGY HEADLINES MAKING NEWS
- Receptor BioLogix acquires Aphton assets
- Receptor BioLogix has acquired the cancer vaccine Insegia and other assets of Aphton Corp. in a Chapter 11 bankruptcy sale.
- complete brief
- European committee gives negative ruling on Tarceva
- OSI Pharmaceuticals announced that its development partner Roche had been given a negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) for Tarceva in combination with gemcitabine chemotherapy as a first-line oral therapy for advanced metastatic pancreatic cancer.
- complete brief
- Santaris inks $200M collaboration with Enzon
- Santaris Pharma has inked a collaboration deal with Enzon Pharmaceuticals that is potentially worth more than $200 million.
- complete brief
- Researchers say Gleevec linked to heart damage
- A team of researchers has concluded that the cancer drug Gleevec may cause serious heart damage.
- complete brief
- FDA approves Gemzar for ovarian cancer
- The FDA has OK'd Eli Lilly's Gemzar in combination with carboplatin for the treatment of recurrent ovarian cancer, marking the fourth approval for the drug.
- complete brief
We’ve Got News For You!
How do you get your oncology industry news? Click here to learn more about OBR Daily, our exclusive and FREE daily e-newsletter summarizing and prioritizing oncology industry news headlines, followed by the broader pharma/biotech industry news.
ARE YOU A CATALYST?
We at OBR believe you are. That's why we are dedicated to providing you with instantaneous oncology news, provocative journalism, topical discussion, and a place to track performance of oncology products, companies, and people.
Become a catalyst. Subscribe today.
ALWAYS WANTED TO WRITE AN ARTICLE?
We always welcome
submissions and ideas
for articles. If you would
like to submit an article or
begin the process of
developing an article
please contact us at
submissions@oncbiz.com
or [415] 332-3327.